Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
David S. Siegel, MD, PhD
Chief of the Myeloma Division
Hackensack University Medical Center
NJ
Chief of the Myeloma Division
Hackensack University Medical Center
NJ
Authored Items
Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework
James T. Kenney, RPh, MBA
,
Anuja Roy, PhD, MBA
,
Jonathan K. Kish, PhD, MPH
,
Lisa M. Bloudek, PharmD, MS
,
David S. Siegel, MD, PhD
,
Sundar Jagannath, MD
,
Denise Globe, PhD
,
Emil T. Kuriakose, MD
,
Kristen Migliaccio-Walle, BS
June 2015, Vol 8, No 4
in
Business
Last modified: June 23, 2015